NCT02031432View on ClinicalTrials.gov

CORAL XT - Open-label Extension Trial of the CORAL Trial

PHASE3CompletedINTERVENTIONAL

Enrollment

76

Participants

Timeline

Start Date

December 18, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

May 3, 2016

Conditions

PainNeoplasmsChronic Pain

Interventions

DRUG

Cebranopadol

Film-coated tablet; strengths: 200, 400, or 600 µg

Trial Locations (22)

1090

AT004, Vienna

1330

BG008, Sofia

1407

BG003, Sofia

BG004, Sofia

2730

DK004, Herlev

4400

HU011, Nyíregyháza

4564

DE008, Böhlen

9000

DK006, Aalborg

9100

BE001, Sint-Niklaas

9700

BG001, Shumen

11000

RS003, Belgrade

21204

RS002, Kamenitz

23000

RS005, Zrenjanin

81377

DE010, Munich

400015

RO002, Cluj-Napoca

42-500

PL012, Będzin

41-300

PL014, Dąbrowa Górnicza

80-208

PL003, Gdansk

44-100

PL010, Gliwice

851 07

SK004, Bratislava

08001

SK001, Prešov

018 52

SK005, Pruské

All Listed Sponsors

lead

Tris Pharma, Inc.

INDUSTRY

NCT02031432 - CORAL XT - Open-label Extension Trial of the CORAL Trial | Biotech Hunter | Biotech Hunter